We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Analytical Cannabis Logo
Home > News > Science & Health > Content Piece

Researcher Recognized for Work on Promising Synthetic CBD-derived Drug

Published: Aug 22, 2018   
Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.

Emerald Health Pharmaceuticals has announced that Carmen Navarrete, Ph.D., a scientist involved in research on EHP's lead product candidate, EHP-101, a patented synthetic cannabidiol (CBD)-derived new chemical entity (NCE), received an award for her post-doctoral presentation on EHP-101 at the 28th Annual International Cannabinoid Research Society (ICRS) Symposium held in Leiden, Netherlands. The award recognizes extraordinary achievements in scientific innovation from all fields of cannabinoid research.

"We are very proud of Dr. Navarrete's receipt of this prestigious award for her work on EHP-101," said Jim DeMesa, M.D., Chief Executive Officer of EHP. "We believe that EHP-101's demonstrated potential as a disease-modifying treatment for multiple sclerosis and scleroderma showcases the beginnings of what our industry can achieve. The recognition of this distinguished award underscores the vision and dedication of the teams behind EHP-101, and further strengthens our pursuit to help patients with these serious, incurable diseases."

Dr. Navarrete, Senior Scientist at Vivacell Biotechnology España, a company involved in a research collaboration with EHP, received the award for her post-doctoral presentation entitled, "Effect of Oral VCE-004.8, a Cannabidiol Quinol Derivative, on Experimental Autoimmune Encephalomyelitis", which provided evidence that EHP-101 (previously known as VCE-004.8) is a promising small molecule to modulate relevant multiple sclerosis targets, having PPARγ and CB2-mediated anti-inflammatory activity, and the potential to enhance remyelination through the induction of hypoxia-inducible factor (HIF)-dependent neuroprotective pathway (destruction of myelin around nerves is the primary feature of multiple sclerosis). EHP-101 is expected to enter a Phase I clinical study before year end.

The International Cannabinoid Research Society (ICRS) is the most prestigious global organization dedicated to scientific research relating to and acting as a source for impartial information on cannabis and cannabinoids.

This article has been republished from materials provided by Emerald Health Pharmaceuticals. Note: material may have been edited for length and content. For further information, please contact the cited source.


Like what you just read? You can find similar content on the topic tag shown below.

Science & Health

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter